Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 56.1% in February

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 572 shares, a decrease of 56.1% from the January 29th total of 1,303 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 8,025 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 8,025 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are short sold.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of large investors have recently made changes to their positions in GNOM. IFP Advisors Inc raised its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% in the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after buying an additional 489 shares during the period. Atria Investments Inc grew its stake in shares of Global X Genomics & Biotechnology ETF by 12.6% in the 2nd quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after buying an additional 2,073 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in Global X Genomics & Biotechnology ETF by 86.7% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock valued at $188,000 after buying an additional 10,358 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares during the last quarter. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of GNOM traded down $0.34 on Friday, reaching $47.47. The stock had a trading volume of 4,095 shares, compared to its average volume of 8,513. Global X Genomics & Biotechnology ETF has a 12-month low of $27.20 and a 12-month high of $51.42. The firm has a market capitalization of $51.74 million, a price-to-earnings ratio of -20.29 and a beta of 1.22. The company has a 50-day simple moving average of $47.30 and a 200-day simple moving average of $43.37.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, January 7th. Stockholders of record on Tuesday, December 30th were paid a $0.5912 dividend. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is currently -26.50%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.